Literature DB >> 10023781

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival.

G Meinhardt1, C M Wendtner, M Hallek.   

Abstract

Chronic lymphocytic leukemia is a malignant disease characterized by clonal expansion of relatively mature B-lymphocytes with a high percentage of cells arrested in the nonproliferative G0/G1 cell cycle phase. Possibly reflecting the clinical heterogeneity observed in patients, various signaling pathways may become affected during the initiation and course of this disease. This review discusses frequent alterations concerning proliferative, differentiation-inducing, and apoptotic pathways elucidated in the recent years that have improved our understanding of this disease.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10023781     DOI： 10.1007/s001090050351

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


  14 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

2.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

3.  Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.

Authors:  Vladimir Jurisic; Natasa Colovic; Nada Kraguljac; Henry Dushan Atkinson; Milica Colovic
Journal:  Med Oncol       Date:  2008-01-09       Impact factor: 3.064

Review 4.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

5.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

6.  The role of Ca2+ on the DADS-induced apoptosis in mouse-rat hybrid retina ganglion cells (N18).

Authors:  Hui-Lu Lin; Jai-Sing Yang; Jen-Hung Yang; Seng-Sheen Fan; Wen-Cheng Chang; Yu-Ching Li; Jing-Gung Chung
Journal:  Neurochem Res       Date:  2006-05-03       Impact factor: 3.996

7.  Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors:  M F Mulas; C Abete; D Pulisci; A Pani; B Massidda; S Dessì; A Mandas
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

8.  β1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice.

Authors:  Stephen R Spindler; Patricia L Mote; Rui Li; Joseph M Dhahbi; Amy Yamakawa; James M Flegal; Daniel R Jeske; Rui Li; Alex L Lublin
Journal:  Age (Dordr)       Date:  2013-01-15

Review 9.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

Review 10.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.